Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 122-129 , August 2009

Supporting the Veterinary Cancer Patient on Chemotherapy: Neutropenia and Gastrointestinal Toxicity

  • David M. Vail, DVM, DACVIM (Oncology)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: David M. Vail, DVM, DACVIM (Oncology), University of Wisconsin–Madison, School of Veterinary Medicine, 2015 Linden Dr, Madison, WI 53706

References 

  1. Ferrell B, Paice J, Koczywas M. New standards and implications for improving the quality of supportive oncology practice. J Clin Oncol. 2008;26:3824–3831
  2. Chun R, Garrett L, BacEwen EG. Cancer chemotherapy. In:  Withrow SJ,  MacEwen EG editor. Small Animal Clinical Oncology. (ed 3). Philadelphia: WB Saunders; 2001;p. 92–118
  3. Bronden LB, Rutteman GR, Flagstad A, et al. Study of dog and cat owners' perceptions of medical treatment for cancer. Vet Rec. 2003;152:77–80
  4. Mellanby RJ, Herrtage ME, Dobson JM. Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma. J Small Anim Pract. 2003;44:100–103
  5. Tzannes S, Hammond MF, Murphy S, et al. Owners ‘perception of their cats' quality of life during COP chemotherapy for lymphoma. J Feline Med Surg. 2008;10:73–81
  6. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol. 2004;2:194–213
  7. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009;59:42–55
  8. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J Vet Pharmacol Ther. 2004;27:227–229
  9. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther. 2004;27:257–264
  10. Mealey KL, Munyard KA, Bentjen SA. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol. 2005;131:193–196
  11. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc. 2003;223:1453–14551434
  12. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A. 2004;101:11725–11730
  13. Geyer J, Doring B, Godoy JR, et al. Frequency of the nt230 (del4) MDR1 mutation in collies and related dog breeds in Germany. J Vet Pharmacol Ther. 2005;28:545–551
  14. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1delta (multidrug sensitivity) polymorhism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc. 2008;233:921–924
  15. Mealey KL, Fidel J, Gay JM, et al. ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med. 2008;22:996–1000
  16. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  17. Walji N, Chan AK, Peake DR. Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J. 2008;84:418–427
  18. Kearney N, Friese C. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: implications for oncology nurses. Eur J Oncol Nurs. 2008;12:14–25
  19. Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol. 2008;6:199–208
  20. Kisseberth WC, Vail DM, Yaissle J, et al. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a veterinary cooperative oncology group study. J Vet Intern Med. 2008;22:83–88
  21. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med. 1993;7:235–240
  22. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007;13:181–198
  23. Rolston KVI. The infectious diseases society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis. 2004;39:S44–S48
  24. Reagan WJ, Murphy D, Battaglino M, et al. Antibodies to canine granulocyte colony-stimulating factor induce persistent neutropenia. Vet Pathol. 1995;32:374–378
  25. Cowgill LD. Use of recombinant human erythropoietin. In:  Kirk RW,  Bonagura JD editor. Current Veterinary Therapy XII: Small Animal Practice. Philadelphia: WB Saunders; 1995;p. 961
  26. Obradovich JE, Ogilvie GK, Stadler-Morris S, et al. Effect of recombinant canine granulocyte colony-stimulating factor on peripheral blood neutrophil counts in normal cats. J Vet Intern Med. 1993;7:65–67
  27. Obradovich JE, Ogilvie GK, Powers BE, et al. Evaluation of recombinant canine granulocyte colony-stimulating factor as an inducer of granulopoiesis. A pilot study J Vet Intern Med. 1991;5:75–79
  28. Ogilvie GK, Obradovich JE, Cooper MF, et al. Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog. J Vet Intern Med. 1992;6:44–47
  29. Fulton R, Gasper PW, Ogilvie GK, et al. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats. Exp Hematol. 1991;19:759–767
  30. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196–205
  31. Chretin JD, Rassnick KM, Shaw NA, et al. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. J Vet Intern Med. 2007;21:141–148
  32. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–995
  33. In:  Waaij D,  Verhoef J editor. New criteria for the antimidrobial therapy: maintenance of digestive tract colonization resistance (Excerpta Medica International Congress Series). Amsterdam: Elsevier Science; 1979;p. 43–53
  34. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494
  35. Naeim A, Dy SM, Lorenz KA, et al. Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol. 2008;26:3903–3910
  36. Antiemesis: The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
  37. Ramsey DS, Kincaid K, Watkins JA, et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008;31538–31543
  38. Sedlacek HS, Ramsey DS, Boucher JF, et al. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. J Vet Pharmacol Ther. 2008;31:533–537
  39. Conder GA, Sedlacek HS, Boucher JF, et al. Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. J Vet Pharmacol Ther. 2008;31:528–532
  40. Benchaoui HA, Siedek EM, de la Puente-Redondo VA, et al. Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. Vet Rec. 2007;161:444–447
  41. de la Puente-Redondo VA, Seidek EM, Benchaoui HA, et al. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. J Small Anim Pract. 2007;48:93–98
  42. de la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res. 2007;68:48–56
  43. Vail DM, Rodabaugh HS, Conder GA, et al. Efficacy of injectable maropitant (Cerenia™) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. Vet Comp Oncol. 2007;5:38–46
  44. Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther. 2008;31:220–229

 Author disclosure of potential conflicts of interest: The author has received research funding and is a paid consultant for Pfizer Animal Health, Inc.

PII: S1938-9736(09)00015-4

doi: 10.1053/j.tcam.2009.02.004

Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 122-129 , August 2009

Article Tools

* Image Usage & Resolution